Moderna Shares Skyrocket 100% on Breakthrough Skin Cancer Vaccine Results

Moderna shares have surged by nearly 100% after the biotech company announced that its mRNA vaccine, developed in collaboration with Merck, has shown promising results in a large trial for skin cancer.

The trial, which involved over 1,000 patients, demonstrated that the combination of Moderna's messenger RNA technology and Merck's immunotherapy showed significant improvements in overall survival rates compared to standard treatments.

This breakthrough is significant as it highlights the potential of mRNA vaccines not just for COVID-19 but also for other types of cancer.